Ikuo Iijima
Ikuo Iijima publishes mostly in Organic Chemistry, Molecular Biology and Pharmacology, on topics such as Chemical synthesis and alkaloids, Synthesis and bioactivity of alkaloids and Organic Chemistry Cycloaddition Reactions.
- World rank
- #5,700,922 of 7,710,434 ranked researchers
- Rank in United States
- #1,417,843 of 1,627,098
- Works
- 53
- Citations
- 615
- Citations per work
- 11.6
What does Ikuo Iijima research?
Ikuo Iijima's work is mostly in Chemistry (51%), Biochemistry, Genetics and Molecular Biology (14%), Pharmacology, Toxicology and Pharmaceutics (9%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Physical Sciences2751.4%
- Chemistry2751.4%
- Life Sciences1426.0%
- Everything else815.8%
- Health Sciences46.8%
- Medicine46.8%
- 1Organic Chemistry51% of their works
- 2Molecular Biology14% of their works
- 3Pharmacology9% of their works
- 4Pharmacology4% of their works
- 5Plant Science3% of their works
- 6Oncology3% of their works
Research topics
- Chemical synthesis and alkaloids
- Synthesis and bioactivity of alkaloids
- Organic Chemistry Cycloaddition Reactions
- Alkaloids: synthesis and pharmacology
- Asymmetric Synthesis and Catalysis
- Synthesis and pharmacology of benzodiazepine derivatives
- Synthesis and Characterization of Heterocyclic Compounds
- Synthesis and Biological Evaluation
Which keywords describe Ikuo Iijima's research?
The keywords of their largest research topics: Synthesis, Alkaloids, Anticancer, Biological Evaluation, Cytotoxicity, Anticancer Agents, Amaryllidaceae and Asymmetric Synthesis.
- Quinoxaline
- Antimicrobial
- Organocatalysis
- Kratom
- DNA-Interactive Agents
- Organic Chemistry
- Beta-Carboline Alkaloids
- Asymmetric Synthesis
- Anticancer Agents
- Biological Evaluation
- Alkaloids
- Synthesis
- Anticancer
- Cytotoxicity
- Amaryllidaceae
- Galanthamine
- Pharmacological Functions
- Reactivity
- Enantioselective Reactions
- Mitragyna Speciosa
- Pyrrolobenzodiazepines
- Antimicrobial Activity
- Triazines
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 23 words, with their numbers
- Synthesis365 topics
- Alkaloids182 topics
- Anticancer172 topics
- Biological Evaluation163 topics
- Cytotoxicity142 topics
- Anticancer Agents132 topics
- Amaryllidaceae121 topic
- Asymmetric Synthesis122 topics
- Galanthamine121 topic
- Beta-Carboline Alkaloids81 topic
- Pharmacological Functions81 topic
- Organic Chemistry71 topic
- Reactivity71 topic
- DNA-Interactive Agents61 topic
- Enantioselective Reactions61 topic
- Kratom61 topic
- Mitragyna Speciosa61 topic
- Organocatalysis61 topic
- Pyrrolobenzodiazepines61 topic
- Antimicrobial51 topic
- Antimicrobial Activity51 topic
- Quinoxaline51 topic
- Triazines51 topic
Where does Ikuo Iijima work?
Ikuo Iijima's main affiliation in the publication record is Tanabe Research Laboratories, United States.
How many publications and citations does Ikuo Iijima have?
OpenAlex counts 53 works and 615 citations for Ikuo Iijima, an h-index of 10, ranking #5,700,922 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Ikuo Iijima. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.